WallStSmart

Johnson Controls International PLC (JCI)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson Controls International PLC generates 100% more annual revenue ($24.43B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 14.4%. VRTX appears more attractively valued with a PEG of 1.69. VRTX earns a higher WallStSmart Score of 68/100 (B-).

JCI

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 7.0Value: 4.3Quality: 5.0
Piotroski: 5/9Altman Z: 1.11

VRTX

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.61
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for JCI.

VRTXUndervalued (+52.4%)

Margin of Safety

+52.4%

Fair Value

$949.55

Current Price

$446.83

$502.72 discount

UndervaluedFair: $949.55Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JCI3 strengths · Avg: 8.7/10
Market CapQuality
$89.11B9/10

Large-cap with strong market position

Return on EquityProfitability
26.1%9/10

Every $100 of equity generates 26 in profit

EPS GrowthGrowth
38.9%8/10

Earnings expanding 38.9% YoY

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6110/10

Safe zone — low bankruptcy risk

Market CapQuality
$114.33B9/10

Large-cap with strong market position

Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

JCI3 concerns · Avg: 2.7/10
PEG RatioValuation
1.984/10

Expensive relative to growth rate

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.112/10

Distress zone — elevated risk

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

P/E RatioValuation
26.7x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : JCI

The strongest argument for JCI centers on Market Cap, Return on Equity, EPS Growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : JCI

The primary concerns for JCI are PEG Ratio, P/E Ratio, Altman Z-Score. A P/E of 44.7x leaves little room for execution misses.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

JCI profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

JCI carries more volatility with a beta of 1.34 — expect wider price swings.

JCI is growing revenue faster at 8.2% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (68/100 vs 59/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson Controls International PLC

INDUSTRIALS · BUILDING PRODUCTS & EQUIPMENT · USA

Johnson Controls International plc is an Irish-domiciled multinational conglomerate headquartered in Cork, Ireland, that produces fire, HVAC, and security equipment for buildings.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?